Therapeutic potential of neuropeptide Y (NPY) receptor ligands

Wahlestedt, Claes

doi:10.1002/emmm.201000100

Cited by 221 publications

(205 citation statements)

References 123 publications

(142 reference statements)

Supporting

Mentioning

193

Contrasting

Unclassified

Order By: Relevance

“…As the biomarker for obesity, NPY is a major mediator in promoting energy storage [104], which regulates food intake, fat deposition and metabolism via various G-proteincoupled NPY receptors including NPY receptor subtype 1, 2, and 5 [105,106]. For example, the NPY receptor sub-type 5 antagonist, Velneperit, has been identified in clinical tests as a potential anti-obesity drug [107,108].…”

Section: The Role Of Npy and Agrp In Sga-induced Weight Gainmentioning

confidence: 99%

Ameliorating antipsychotic-induced weight gain by betahistine: Mechanisms and clinical implications

Lian

Huang

Pai

et al. 2016

Pharmacological Research

View full text Add to dashboard Cite

Second generation antipsychotic drugs (SGAs) cause substantial body weight gain/obesity and other metabolic side-effects such as dyslipidaemia. Their antagonistic affinity to the histaminergic H1 receptor (H1R) has been identified as one of the main contributors to weight gain/obesity side-effects. The effects and mechanisms of betahistine (a histaminergic H1R agonist and H3 receptor antagonist) have been investigated for ameliorating SGA-induced weight gain/obesity in both animal models and clinical trials. It has been demonstrated that co-treatment with betahistine is effective in reducing weight gain, associated with olanzapine in drug-naïve patients with schizophrenia, as well as in the animal models of both drug-naïve rats and rats with chronic, repeated exposure to olanzapine. Betahistine co-treatment can reduce food intake and increase the effect of thermogenesis in brown adipose tissue by modulating hypothalamic H1R-NPY-AMPKα (NPY: neuropeptide Y; AMPKα: AMP-activated protein kinase α) pathways, and ameliorate olanzapineinduced dyslipidaemia through modulation of AMPKα-SREBP-1-PPARα-dependent pathways (SREBP-1: Sterol regulatory element binding protein 1; PPARα: Peroxisome proliferator-activated receptor-α) in the liver. Although reduced locomotor activity was observed from antipsychotic treatment in rats, betahistine did not affect locomotor activity. Importantly, betahistine co-treatment did not influence the effects of antipsychotics on serotonergic receptors in the key brain regions for antipsychotic therapeutic efficacy. However, betahistine co-treatment reverses the upregulated dopamine D2 binding caused by chronic olanzapine administration, which may be beneficial in reducing D2 supersensitivity often observed in chronic antipsychotic treatment. Therefore, these results provide solid evidence supporting further clinical trials in treating antipsychotics-induced weight gain using betahistine in patients with schizophrenia and other mental disorders.

show abstract

Section: The Role Of Npy and Agrp In Sga-induced Weight Gainmentioning

confidence: 99%

Ameliorating antipsychotic-induced weight gain by betahistine: Mechanisms and clinical implications

Lian

Huang

Pai

et al. 2016

Pharmacological Research

View full text Add to dashboard Cite

show abstract

“…Y 1 , Y 2 , and Y 5 can be associated with different aspects of oncogenesis and angiogenesis. In peripheral organs, NPY receptors can be found in colon, kidney, adrenal gland, reproductive organs, testis, and breast (15).…”

Section: Npy Systemmentioning

confidence: 99%

Targeting Neuropeptide Receptors for Cancer Imaging and Therapy: Perspectives with Bombesin, Neurotensin, and Neuropeptide-Y Receptors

et al. 2014

View full text Add to dashboard Cite

Learning Objectives: On successful completion of this activity, participants should be able to list and discuss (1) the presence of bombesin receptors, neurotensin receptors, or neuropeptide-Y receptors in some major tumors; (2) the perspectives offered by radiolabeled peptides targeting these receptors for imaging and therapy; and (3) the choice between agonists and antagonists for tumor targeting and the relevance of various PET radionuclides for molecular imaging.Financial Disclosure: The authors of this article have indicated no relevant relationships that could be perceived as a real or apparent conflict of interest. CME Credit: SNMMI is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing education for physicians. SNMMI designates each JNM continuing education article for a maximum of 2.0 AMA PRA Category 1 Credits. Physicians should claim only credit commensurate with the extent of their participation in the activity. For CE credit, SAM, and other credit types, participants can access this activity through the SNMMI website (http://www.snmmilearningcenter.org) through October 2017.Receptors for some regulatory peptides are highly expressed in tumors. Selective radiolabeled peptides can bind with high affinity and specificity to these receptors and exhibit favorable pharmacologic and pharmacokinetic properties, making them suitable agents for imaging or targeted therapy. The success encountered with radiolabeled somatostatin analogs is probably the first of a long list, as multiple peptide receptors are now recognized as potential targets. This review focuses on 3 neuropeptide receptor systems (bombesin, neurotensin, and neuropeptide-Y) that offer high potential in the field of nuclear oncology. The underlying biology of these peptide/receptor systems, their physiologic and pathologic roles, and their differential distribution in normal and tumoral tissues are described with emphasis on breast, prostate, and lung cancers. Radiolabeled analogs that selectively target these receptors are highlighted.

show abstract

“…Bir NPY2R antagonistinin örneğin BIIE0246'nin (N- NPY (veya bir NPY1 agonisti) antidepresan ya da bilişsel yetilerin düzel-tilmesinde bir ajan olarak kullanılabilmesi olasıdır. [108] Halen araştırılması gereken bir konu olmakla birlikte NPY'nin terapötik potansiyele sahip olduğu düşünülmektedir.…”

Section: Büyüme Ve Ergenlik (Puberte)unclassified

Neuropeptide Y and Stress

Gülsün¹,

Tamam²

2012

Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychia

View full text Add to dashboard Cite

ÖZETStres ve bireysel baş etme yetilerinin nörobiyolojik yönü birçok araştırmacının ilgi odağı olmuştur. Bir dizi çalışmada genetik değişkenler ile strese tepki düzeyleri ve yaşam olayları arasında bir ilişki olduğu gösterilmiştir. Nöropeptid Y stres esnekliğini düzenleyen sistemlerden biridir. Uzun süreli ya da tekrarlayan stres durumlarında nöropeptid Y beynin anahtar bölgelerinden salınır. Bu sistem stresle ilgili bozukluklara yatkınlığı farklı kişilerde farklı esneklikte işleyiş gösterir. Gen-çevre etkileşimleri için özellikle ilgi çekici olan strese duyarlı sinyal moleküllerini kodlayan genlerin değişimidir. Bu durum strese yatkınlığa ya da esnekliğe katkıda bulunabilir. Nöropeptid Y sistemi de strese davranışsal uyumda anahtar rol oynamaktadır. Nöropeptid Y düzeyinin azalmış olması tedaviye dirençli depresyonda ve travma sonrası stres bozukluğunda da gözlenmiştir. Düşük nöropeptid Y ekspresyonunun ya da strese yanıt olarak nöropeptid Y sisteminin yeterince işlevsel olmaması ve sonucunda ortaya çıkan stres esnekliğinin az olması stresle ilişkili bozukluklara yatkınlığı arttırabilmektedir. Anahtar Sözcükler: Nöropeptid Y, stres, stres esnekliği ABSTRACTThe neurobiological aspects of stress and coping skills has been the focus of interest for many researchers. Some of the studies has shown that there is a significant relationship among genetically variables, stress response and life events. Neuropeptide Y is one of the systems regulating the stress response. Under the prolonged or repeated trauma neuropeptide Y is released from the brain's key areas. This system shows different levels of functioning in individuals with different levels of resilience. There is particular interest in the variations of genes that encode stress-sensitive signaling molecules during geneenvironment interaction. This condition may contribute to susceptibility of stress or stress resilience. Neuropeptide Y system plays a key role in the adaptation to behavioral stress. The reduced levels of neuropeptide Y have also been observed in treatment-resistant depression and posttraumatic stress disorder. Lower level of neuropeptide Y expression and dysfunctional neuro-

show abstract

Therapeutic potential of neuropeptide Y (NPY) receptor ligands

Cited by 221 publications

References 123 publications

Ameliorating antipsychotic-induced weight gain by betahistine: Mechanisms and clinical implications

Ameliorating antipsychotic-induced weight gain by betahistine: Mechanisms and clinical implications

Targeting Neuropeptide Receptors for Cancer Imaging and Therapy: Perspectives with Bombesin, Neurotensin, and Neuropeptide-Y Receptors

Neuropeptide Y and Stress

Contact Info

Product

Resources

About